|
1
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li C, Heidt DG, Dalerba P, et al:
Identification of pancreatic cancer stem cells. Cancer Res.
67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110.
2007.PubMed/NCBI
|
|
6
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human
colon-cancer-initiating cells. Nature. 445:111–115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dalerba P, Dylla SJ, Park IK, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du L, Wang H, He L, et al: CD44 is of
functional importance for colorectal cancer stem cells. Clin Cancer
Res. 14:6751–6760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takaishi S, Okumura T, Tu S, et al:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang EH, Hynes MJ, Zhang T, et al:
Aldehyde dehydrogenase 1 is a marker for normal and malignant human
colonic stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shmelkov SV, Butler JM, Hooper AT, et al:
CD133 expression is not restricted to stem cells, and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
12
|
Bao S, Wu Q, Sathornsumetee S, et al: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al Dhaybi R, Sartelet H, Powell J and
Kokta V: Expression of CD133+ cancer stem cells in
childhood malignant melanoma and its correlation with metastasis.
Mod Pathol. 23:376–380. 2010.
|
|
14
|
Artells R, Moreno I, Diaz T, et al: Tumour
CD133 mRNA expression and clinical outcome in surgically resected
colorectal cancer patients. Eur J Cancer. 46:642–649. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baba T, Convery PA, Matsumura N, et al:
Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tirino V, Desiderio V, Paino F, et al:
Human primary bone sarcomas contain CD133+ cancer stem
cells displaying high tumorigenicity in vivo. FASEB J.
25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Griguer CE, Oliva CR, Gobin E, et al:
CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE.
3:e36552008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bidlingmaier S, Zhu X and Liu B: The
utility and limitations of glycosylated human CD133 epitopes in
defining cancer stem cells. J Mol Med. 86:1025–1032. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Futschik M, Jeffs A, Pattison S, et al:
Gene expression profiling of metastatic and nonmetastatic
colorectal cancer cell lines. Genome Lett. 1:26–34. 2002.
View Article : Google Scholar
|
|
20
|
Madjd Z, Mehrjerdi AZ, Sharifi AM,
Molanaei S, Shahzadi SZ and Asadi-Lari M: CD44+ cancer
cells express higher levels of the anti-apoptotic protein Bcl-2 in
breast tumours. Cancer Immun. 9:42009.
|
|
21
|
Hao JL, Cozzi PJ, Khatri A, Power CA and
Li Y: CD147/EMMPRIN and CD44 are potential therapeutic targets for
metastatic prostate cancer. Curr Cancer Drug Targets. 10:287–306.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huerta S, Harris DM, Jazirehi A, et al:
Gene expression profile of metastatic colon cancer cells resistant
to cisplatin-induced apoptosis. Int J Oncol. 22:663–670.
2003.PubMed/NCBI
|
|
23
|
Kawamoto H, Yuasa T, Kubota Y, et al:
Characteristics of CD133(+) human colon cancer SW620 cells. Cell
Transplant. 19:857–864. 2010.
|
|
24
|
Todaro M, Alea MP, Di Stefano AB, et al:
Colon cancer stem cells dictate tumor growth and resist cell death
by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haraguchi N, Ohkuma M, Sakashita H, et al:
CD133+CD44+ population efficiently enriches
colon cancer initiating cells. Ann Surgical Oncol. 15:2927–2933.
2008.
|
|
26
|
Miletti-Gonzalez KE, Chen S, Muthukumaran
N, et al: The CD44 receptor interacts with P-glycoprotein to
promote cell migration and invasion in cancer. Cancer Res.
65:6660–6667. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wiranowska M, Ladd S, Smith SR and
Gottschall PE: CD44 adhesion molecule and neuro-glial proteoglycan
NG2 as invasive markers of glioma. Brain Cell Biol. 35:159–172.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kojima M, Ishii G, Atsumi N, Fujii S,
Saito N and Ochiai A: Immunohistochemical detection of CD133
expression in colorectal cancer: a clinicopathological study.
Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bendardaf R, Algars A, Elzagheid A, et al:
Comparison of CD44 expression in primary tumours and metastases of
colorectal cancer. Oncol Rep. 16:741–746. 2006.PubMed/NCBI
|
|
30
|
Huh JW, Kim HR, Kim YJ, et al: Expression
of standard CD44 in human colorectal carcinoma: association with
prognosis. Pathol Int. 59:241–246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu C, Kelnar K, Liu B, et al: The
microRNA miR-34a inhibits prostate cancer stem cells and metastasis
by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao AC, Lou W, Dong JT and Isaacs JT: CD44
is a metastasis suppressor gene for prostatic cancer located on
human chromosome 11p13. Cancer Res. 57:846–849. 1997.PubMed/NCBI
|
|
33
|
Abetamann V, Kern HF and Elsasser HP:
Differential expression of the hyaluronan receptors CD44 and RHAMM
in human pancreatic cancer cells. Clin Cancer Res. 2:1607–1618.
1996.PubMed/NCBI
|
